Device Trial Radar · NCT07792772
Arrhythmia Detection With MEMO Patch Plus in Patients With Acute Heart Failure
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Jul 11, 2023
Primary completion
Apr 30, 2026
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- HUINNO Co., LtdNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Asan Medical Center; Korea University Anam Hospital; Seoul National University Bundang Hospital
- First posted
- Aug 28, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective, multicenter, open-label, single-group exploratory clinical trial evaluates the clinical effectiveness of extended electrocardiographic monitoring with MEMO Patch Plus for detecting clinically significant arrhythmias in adult patients hospitalized with acute heart failure. Eligible participants receive continuous electrocardiographic monitoring with MEMO Patch Plus for up to 14 days during hospitalization and again for up to 14 days after discharge. Participants return the post-discharge device by mail, review the monitoring results approximately 6 weeks after discharge, and complete a final follow-up assessment approximately 12 weeks after discharge. The primary outcome is the proportion of participants in whom a clinically significant arrhythmia is detected. Secondary outcomes include the detection of other arrhythmias, changes in clinical management following an arrhythmia diagnosis, major clinical events through 3 months after discharge, atrial fibrillation or atrial flutter burden, the longest atrial fibrillation or atrial flutter episode, and adherence to MEMO Patch Plus monitoring.
Conditions
- Acute Heart Failure (AHF)
- Cardiac Arrhythmia
Interventions
MEMO Patch PlusDevice
MEMO Patch Plus is a wearable, noninvasive electrocardiographic monitoring device designed for long-term recording and reproduction of electrocardiographic signals. In this study, eligible participants receive MEMO Patch Plus on Day 1 and wear the device during hospitalization for up to 14 days. At discharge, participants receive another MEMO Patch Plus device and wear it for up to 14 additional days after discharge. The device records electrocardiographic data for the detection of clinically significant and other arrhythmias. Clinically significant arrhythmias include a pause lasting 3 seconds or longer, high-degree or complete atrioventricular block, atrial fibrillation or atrial flutter, supraventricular tachycardia, ventricular tachycardia, and ventricular fibrillation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Clinically Significant Arrhythmias Detected by MEMO Patch PlusTime frame: During inpatient monitoring for up to 14 days and post-discharge monitoring for up to 14 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Seoul National University Bundang Hospital
Gyeonggi-do, South Korea
Asan Medical Center
Seoul, South Korea
Korea University Anam Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.